Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification
Clinical and Translational Science · 2024
DOI: 10.1111/cts.70091 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Jiajia Yuan und 19 weiteren Autor:innen. Beteiligte Einrichtung: Peking University Cancer Hospital and Institute, Beijing, China. Hauptthemen laut MEDLINE: Gene Amplification, Receptor, Fibroblast Growth Factor, Type 2, Stomach Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Infigratinib, an FGFR1‐3 selective oral tyrosine kinase inhibitor, has shown clinical activity in cancers with FGFR alterations. The pharmacokinetics (PK) of infigratinib and its major metabolites have been characterized in global populations. This study examined the PK profile of infigratinib and its metabolites in Chinese patients. In this phase II, open‐label, single‐arm study in China, patients with advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) harboring FGFR2 gene amplification received 125 mg infigratinib orally once daily in a “3 weeks on, 1 week off” schedule for 28‐day cycles. Plasma PK parameters were calculated with a non‐compartmental model. Data were available from 21 patients (19 GC and two GEJ). After a single dose, peak infigratinib plasma concentration was reached at a median time of 3.1 h, with geometric mean C max of 85.9 ng/mL and AUC 0‐ t of 637 h*ng/mL. After 21‐day dosing, geometric mean infigratinib C max,ss of 204 ng/mL was reached at a median of 4.0 h; geometric mean AUC 0‐24,ss was 3060 h*ng/mL. The geometric mean R ac , Cmax (%CV) and R ac , AUC0‐24 (%CV) of infigratinib was 2.5 (113.8) and 5.1 (138.2), respectively. A steady state of infigratinib was reached after continuous dosing for 15 days. The metabolites accounting for >10% of infigratinib were BHS697 and CQM157. The PK profiles of infigratinib and its metabolites in Chinese patients with GC or GEJ were largely consistent with known PK profiles of infigratinib from global populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Peking University Cancer Hospital and Institute, Beijing, China.
- Zhongshan Hospital Affiliated to Fudan University, Shanghai, China.
- Hubei Cancer Hospital, Wuhan, China.
- Fujian Provincial Cancer Hospital, Fuzhou, China.
- Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
- The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
ORCID-Profile: Lingli Zhang, Lin Song, Qiao Sun
Zitieren
APA
Yuan, J., Shen, L., Liu, T. S., Xu, H., Yang, J., Wei, J., Jiang, H., Deng, Y., Pan, H., Wang, Y., Zhang, X., Peng, Z., Qi, C., Zhang, L., Hsu, P., Song, L., Mu, L., Sun, Q., Gong, J., & Lyu, C. (2024). Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification. Clinical and Translational Science. https://doi.org/10.1111/cts.70091
Vancouver
Yuan J, Shen L, Liu TS, Xu H, Yang J, Wei J, et al. Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification. Clinical and Translational Science. 2024. doi:10.1111/cts.70091
BibTeX
@article{Yuan2024,
author = {Yuan, Jiajia and Shen, Lin and Liu, Tian Shu and Xu, HuiTing and Yang, Jianwei and Wei, Jia and Jiang, Haiping and Deng, Yanhong and Pan, Hongming and Wang, Yusheng and Zhang, Xiaotian and Peng, Zhi and Qi, Changsong and Zhang, Lingli and Hsu, Peiwen and Song, Lin and Mu, Lei and Sun, Qiao and Gong, Jifang and Lyu, Cheng},
title = {Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.70091}
}
EUVIMED